STERIS plc (NYSE:STE – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $278.00.
A number of analysts recently commented on STE shares. KeyCorp dropped their price target on STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. UBS Group started coverage on STERIS in a research note on Tuesday. They issued a “buy” rating on the stock. Weiss Ratings lowered STERIS from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 27th. Piper Sandler restated an “overweight” rating and issued a $270.00 price objective on shares of STERIS in a research note on Thursday, May 21st. Finally, Wall Street Zen downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 6th.
Check Out Our Latest Report on STERIS
STERIS Price Performance
STERIS (NYSE:STE – Get Free Report) last announced its earnings results on Monday, May 11th. The medical equipment provider reported $2.83 EPS for the quarter, missing the consensus estimate of $2.86 by ($0.03). STERIS had a net margin of 13.18% and a return on equity of 14.15%. The firm had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.59 billion. During the same quarter in the prior year, the company earned $2.74 EPS. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. As a group, analysts anticipate that STERIS will post 11.18 earnings per share for the current fiscal year.
STERIS Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Friday, June 26th. Stockholders of record on Monday, June 8th were given a $0.63 dividend. The ex-dividend date of this dividend was Monday, June 8th. This represents a $2.52 annualized dividend and a dividend yield of 1.2%. STERIS’s payout ratio is 31.78%.
Insider Buying and Selling at STERIS
In other news, CEO Daniel A. Carestio sold 1,374 shares of STERIS stock in a transaction on Friday, June 5th. The stock was sold at an average price of $212.00, for a total value of $291,288.00. Following the completion of the transaction, the chief executive officer directly owned 63,647 shares in the company, valued at approximately $13,493,164. The trade was a 2.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard C. Breeden sold 1,481 shares of STERIS stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $209.51, for a total value of $310,284.31. Following the completion of the transaction, the director owned 38,964 shares of the company’s stock, valued at approximately $8,163,347.64. This trade represents a 3.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 7,328 shares of company stock valued at $1,554,051 in the last 90 days. 1.12% of the stock is currently owned by company insiders.
Institutional Trading of STERIS
A number of institutional investors have recently added to or reduced their stakes in STE. Western Wealth Management LLC purchased a new position in STERIS during the 1st quarter valued at about $25,000. Elevation Wealth Partners LLC lifted its holdings in shares of STERIS by 1,130.0% in the second quarter. Elevation Wealth Partners LLC now owns 123 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 113 shares in the last quarter. Activest Wealth Management lifted its holdings in shares of STERIS by 423.8% in the fourth quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 89 shares in the last quarter. Measured Wealth Private Client Group LLC bought a new position in shares of STERIS in the fourth quarter valued at approximately $28,000. Finally, Geneos Wealth Management Inc. boosted its position in shares of STERIS by 416.0% in the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 104 shares during the period. Hedge funds and other institutional investors own 94.69% of the company’s stock.
STERIS Company Profile
STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.
Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.
Featured Stories
- Five stocks we like better than STERIS
- 3 Value ETFs to Consider as Growth Stocks Lag Behind
- Wintrust: A Quiet Regional Bank Posting Loud Results
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.
